Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline plc    GSK   GB0009252882


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

EU close to concluding preliminary talks with Novavax on COVID vaccine supply - source

share with twitter share with LinkedIn share with facebook
09/24/2020 | 03:00am EDT

BRUSSELS, Sept 23 (Reuters) - Brussels is close to wrapping up preliminary talks with U.S. vaccine maker Novavax for its potential COVID-19 shot, an EU source involved in the negotiations said, as the bloc ramps up its push in the global race to secure supplies.

The move is meant to expand to seven the portfolio of vaccines the 27-country bloc, with a population of 450 million, wants to secure. It would bring doses potentially available to EU countries to more than 2 billion.

"We are at an advanced stage in talks with Novavax," the EU senior official said, who declined to be identified as negotiations are confidential.

The number of doses the EU could secure is still under discussion, the official said, noting that it was likely to be at least 100 million.

A spokesman for the EU executive commission, which is co-leading the talks with vaccine makers, declined to comment. Novavax had no immediate comment.

The EU has already secured 400 million doses of the potential vaccine being developed by AstraZeneca and Oxford University, and 300 million doses of the potential shot being trialled by Sanofi and GlaxoSmithKline.

It is also in talks with Johnson & Johnson, Moderna , CureVac and a partnership of Pfizer and BionTech for nearly 1.3 billion additional doses of their vaccine candidates.

The seventh vaccine would add to the EU portfolio a second protein-based jab, the same technology used by Sanofi and GSK. The EU is also securing shots based on messenger RNA (mRNA) and vector technologies.

"We want to split the risks," the official said, as it is not certain which, if any, of the vaccines under development will prove effective and safe.

If it strikes seven deals, the EU would be ahead of Britain and the United States, which each have concluded six supply contracts so far.

Novavax has already reached supply deals with the United States, Britain, Japan and Canada. It is also one of the potential vaccines covered by the WHO-led procurement facility COVAX.

Crucial for the deals to be finalised is the topping up of an EU emergency fund, which has so far made available 2 billion euros ($2.3 billion) for vaccine purchases. At least another 750 million euros is needed to cover the seven deals, the EU official said.

($1 = 0.8551 euros)

(Reporting by Francesco Guarascio; Editing by Josephine Mason and Jan Harvey)

Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -1.40% 7766 Delayed Quote.2.09%
BIONTECH SE 0.65% 85.36 Delayed Quote.151.95%
GLAXOSMITHKLINE PLC -0.95% 1291.8 Delayed Quote.-27.39%
MODERNA, INC. -5.35% 67.47 Delayed Quote.244.94%
NOVAVAX, INC. -7.90% 80.71 Delayed Quote.1,927.89%
SANOFI -1.10% 77.37 Real-time Quote.-13.67%
share with twitter share with LinkedIn share with facebook
10/30GLAXOSMITHKLINE : Sell rating from Barclays
10/30GLAXOSMITHKLINE : Goldman Sachs reiterates its Buy rating
10/29GLAXOSMITHKLINE : Activists urge 'Big Pharma' to be transparent on COVID-19 vacc..
10/29GLAXOSMITHKLINE : European Commission approves Zejula (niraparib) as first-line ..
10/29GLAXOSMITHKLINE : GSK Nucala (mepolizumab) filings accepted by European Medicine..
10/29GLAXOSMITHKLINE : Credit Suisse remains Neutral
10/29Sanofi raises outlook as speciality care and vaccines lift sales
10/29Sanofi raises outlook as speciality care and vaccines lift sales
10/29Next crop of COVID-19 vaccine developers take more traditional route
10/28GLAXOSMITHKLINE : Q3 2020 results transcript
More news
Sales 2020 34 388 M 44 531 M 44 531 M
Net income 2020 4 863 M 6 298 M 6 298 M
Net Debt 2020 23 094 M 29 906 M 29 906 M
P/E ratio 2020 13,1x
Yield 2020 6,19%
Capitalization 64 302 M 83 307 M 83 269 M
EV / Sales 2020 2,54x
EV / Sales 2021 2,40x
Nbr of Employees 99 437
Free-Float 92,3%
Duration : Period :
GlaxoSmithKline plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GLAXOSMITHKLINE PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 1 748,35 GBX
Last Close Price 1 291,80 GBX
Spread / Highest target 81,9%
Spread / Average Target 35,3%
Spread / Lowest Target -13,3%
EPS Revisions
Emma N. Walmsley Chief Executive Officer & Executive Director
Jonathan Richard Symonds Non-Executive Chairman
Iain James Mackay Chief Financial Officer & Executive Director
Karenann K. Terrell Chief Digital & Technology Officer
Hal V. Barron Executive Director & Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-6.01%361 159
ROCHE HOLDING AG-6.13%275 049
PFIZER INC.-9.44%196 047
MERCK & CO., INC.-17.31%191 944
NOVARTIS AG-22.21%177 493